Rena Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 12

Employees

  • Latest Deal Type
  • M&A

Rena Therapeutics General Information

Description

Developer of Hetero-Duplex oligonucleotides technology designed for a technology platform applicable to drug discovery research of nucleic acid medicines. The company offers Hetero-Duplex oligonucleotides technology nucleic acid medicines, the mechanism associated with a gene that is a therapeutic target is elucidated in medical research or clinical practice, the sequence information of that gene can be used to design pharmaceutical compounds, thereby enabling its clients to facilitate the development of any nucleic acid therapeutics in pipelines.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Global Business Hub Tokyo, 3rd floor, Otemachi Financial City Cube
  • 1-9-2 Otemachi
  • Chiyoda-ku, Tokyo 100-0004
  • Japan
+81
Primary Industry
Drug Discovery
Parent Company
Vertical(s)
Corporate Office
  • Global Business Hub Tokyo, 3rd floor, Otemachi Financial City Cube
  • 1-9-2 Otemachi
  • Chiyoda-ku, Tokyo 100-0004
  • Japan
+81

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Rena Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 21-Nov-2019 Completed Generating Revenue
2. Early Stage VC 30-Jun-2017 Completed Generating Revenue
1. Early Stage VC (Series A) 20-Apr-2015 $5.02M $5.02M Completed Startup
To view Rena Therapeutics’s complete valuation and funding history, request access »

Rena Therapeutics Patents

Rena Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2024089860-A Nucleic acid complex for modulating zic5 expression Active 22-Dec-2022
JP-7933315-B2 Nucleic acid complexes for regulating zic5 expression Active 22-Dec-2022
US-20260185102-A1 Ligand-binding nucleic acid complex Pending 02-Nov-2021
EP-4428238-A1 Ligand-bound nucleic acid complex Pending 02-Nov-2021
EP-4428238-A4 Ligand-bound nucleic acid complex Pending 02-Nov-2021 C07K14/635
To view Rena Therapeutics’s complete patent history, request access »

Rena Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rena Therapeutics Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
DBJ Capital Corporate Venture Capital Minority
Innovation Network Corporation of Japan Growth/Expansion Minority
KSP (Kawasaki) Corporation Minority
To view Rena Therapeutics’s complete investors history, request access »

Rena Therapeutics FAQs

  • When was Rena Therapeutics founded?

    Rena Therapeutics was founded in 2015.

  • Where is Rena Therapeutics headquartered?

    Rena Therapeutics is headquartered in Chiyoda-ku, Japan.

  • What is the size of Rena Therapeutics?

    Rena Therapeutics has 12 total employees.

  • What industry is Rena Therapeutics in?

    Rena Therapeutics’s primary industry is Drug Discovery.

  • Is Rena Therapeutics a private or public company?

    Rena Therapeutics is a Private company.

  • What is Rena Therapeutics’s current revenue?

    The current revenue for Rena Therapeutics is .

  • How much funding has Rena Therapeutics raised over time?

    Rena Therapeutics has raised $10.4M.

  • Who are Rena Therapeutics’s investors?

    DBJ Capital, Innovation Network Corporation of Japan, and KSP (Kawasaki) have invested in Rena Therapeutics.

  • When was Rena Therapeutics acquired?

    Rena Therapeutics was acquired on 21-Nov-2019.

  • Who acquired Rena Therapeutics?

    Rena Therapeutics was acquired by Nippon Shokubai.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process